Soumita De
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Soumita De has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Udo Rudloff
Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
45 shared publications - Anne M. Miermont
Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
44 shared publications - Astin S. Powers
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
44 shared publications - Dandan Li
Rare Tumor Initiative, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
44 shared publications - Humair S. Quadri
Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
44 shared publications - Lesley A. Mathews Griner
Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland
44 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (4) , 2244-2263
Harnessing Membrane-Active Peptides for Selective Cancer Targeting: Phosphatidylserine Recognition by Tilapia Piscidin 4
Membrane-active peptides (MAPs) have garnered significant attention as potential alternatives to conventional cancer therapies, which are frequently limited by severe side effects. Among them, antimicrobial peptides (AMPs) that leverage differences between the plasma membranes of cancer cells and healthy cells are particularly attractive. While several AMPs have demonstrated anticancer potency, structure–function relationship studies are lacking to explain the molecular basis of their selectivity and to help design improved analogs. Here, we contribute to filling this gap by investigating Nile tilapia piscidin 4 (TP4), an AMP with demonstrated activity against several solid organ cancers. First, we discover through biological assays that the anticancer activity of the peptide, which underscores a promising therapeutic window, is associated with increased plasma membrane permeability in cancer cells compared to normal cells and positively (negatively) correlated with enzymes that enrich (deplete) anionic PS in the outer leaflet. Next, we utilize a suite of complementary techniques on model membranes to investigate the interactions of TP4 with membranes, uncovering behaviors not previously observed in related AMPs. Circular dichroism experiments reveal that TP4 preferentially binds to zwitterionic phosphatidylcholine (PC) membranes enriched in anionic PS, while cholesterol markedly impairs binding. X-ray diffraction demonstrates that TP4 disrupts PC–PS membranes by inducing lipid segregation. Covering a range of biologically relevant peptide concentrations with neutron diffraction and reflectometry measurements in fluid bilayers and MD simulations, we unveil how TP4 and associated water gradually insert into the hydrocarbon region and cause convoluted membrane deformations to breach the membrane barriers. These studies highlight the pivotal role of the TP4 polyarginine tail in driving selective membrane binding and disruption on membranes enriched with the anionic lipid PS. Together, our results elucidate the molecular determinants underpinning the selective anticancer effects of TP4, providing a strategic framework for the rational design of advanced membrane-active therapeutics.
- 7 April 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (4) , 2244-2263
Open AccessHarnessing Membrane-Active Peptides for Selective Cancer Targeting: Phosphatidylserine Recognition by Tilapia Piscidin 4
Membrane-active peptides (MAPs) have garnered significant attention as potential alternatives to conventional cancer therapies, which are frequently limited by severe side effects. Among them, antimicrobial peptides (AMPs) that leverage differences between the plasma membranes of cancer cells and healthy cells are particularly attractive. While several AMPs have demonstrated anticancer potency, structure–function relationship studies are lacking to explain the molecular basis of their selectivity and to help design improved analogs. Here, we contribute to filling this gap by investigating Nile tilapia piscidin 4 (TP4), an AMP with demonstrated activity against several solid organ cancers. First, we discover through biological assays that the anticancer activity of the peptide, which underscores a promising therapeutic window, is associated with increased plasma membrane permeability in cancer cells compared to normal cells and positively (negatively) correlated with enzymes that enrich (deplete) anionic PS in the outer leaflet. Next, we utilize a suite of complementary techniques on model membranes to investigate the interactions of TP4 with membranes, uncovering behaviors not previously observed in related AMPs. Circular dichroism experiments reveal that TP4 preferentially binds to zwitterionic phosphatidylcholine (PC) membranes enriched in anionic PS, while cholesterol markedly impairs binding. X-ray diffraction demonstrates that TP4 disrupts PC–PS membranes by inducing lipid segregation. Covering a range of biologically relevant peptide concentrations with neutron diffraction and reflectometry measurements in fluid bilayers and MD simulations, we unveil how TP4 and associated water gradually insert into the hydrocarbon region and cause convoluted membrane deformations to breach the membrane barriers. These studies highlight the pivotal role of the TP4 polyarginine tail in driving selective membrane binding and disruption on membranes enriched with the anionic lipid PS. Together, our results elucidate the molecular determinants underpinning the selective anticancer effects of TP4, providing a strategic framework for the rational design of advanced membrane-active therapeutics.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Secondary validation of candidate genes.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Secondary validation of candidate genes.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Lists of cell lines, antibodies, RNAi kinome screen; and matrix drug combination.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Lists of cell lines, antibodies, RNAi kinome screen; and matrix drug combination.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Schematic layout of the selumetinib versus 26 compounds targeting effector signaling of CNKSR1 screen; and Dose response of MK-2206 and rapamycin in the pancreas cancer cell lines.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Schematic layout of the selumetinib versus 26 compounds targeting effector signaling of CNKSR1 screen; and Dose response of MK-2206 and rapamycin in the pancreas cancer cell lines.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
CNKSR1 promotes MEK inhibition-induced AKT activation.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
CNKSR1 promotes MEK inhibition-induced AKT activation.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Resistance to MEK inhibition in YAPC cells is not due to reactivation of phospho-Extracellular-signal-regulated-kinases (ERK) levels.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Resistance to MEK inhibition in YAPC cells is not due to reactivation of phospho-Extracellular-signal-regulated-kinases (ERK) levels.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
MEK blockade fails to disrupt protein-protein interactions of CNKSR1, KSR1/2, and MEK in CNKSR1low cancer cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
MEK blockade fails to disrupt protein-protein interactions of CNKSR1, KSR1/2, and MEK in CNKSR1low cancer cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Selumetinib fails to recruit CNKSR1 and p-AKT to the plasma membrane in CNKSR1 low cell lines; Proximal ligation of CNKSR1 and p-AKT in CNKSR1 low cell lines treated with vehicle vs selumetinib;CNKSR1 p-AKT PLA signal after treatment with selumetinib is dependent on the presence of both primary antibodies; Silencing of CNKSR1 in the CNKSR1high cell lines abrogates PLA signal; and Immunofluorescence staining of PIP3 and CNKSR1 in YAPC treated with vehicle and selumetinib.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Selumetinib fails to recruit CNKSR1 and p-AKT to the plasma membrane in CNKSR1 low cell lines; Proximal ligation of CNKSR1 and p-AKT in CNKSR1 low cell lines treated with vehicle vs selumetinib;CNKSR1 p-AKT PLA signal after treatment with selumetinib is dependent on the presence of both primary antibodies; Silencing of CNKSR1 in the CNKSR1high cell lines abrogates PLA signal; and Immunofluorescence staining of PIP3 and CNKSR1 in YAPC treated with vehicle and selumetinib.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Dose response of PK-59 cells transfected with scramble siRNA and indicated candidate gene siRNAs; and CNKSR1 immunohistochemical staining in pancreas cancer tissues.